Last reviewed · How we verify
Irbesartan treatment
Irbesartan blocks angiotensin II type 1 receptors, reducing vasoconstriction and aldosterone secretion to lower blood pressure.
Irbesartan blocks angiotensin II type 1 receptors, reducing vasoconstriction and aldosterone secretion to lower blood pressure. Used for Hypertension, Diabetic nephropathy in patients with type 2 diabetes.
At a glance
| Generic name | Irbesartan treatment |
|---|---|
| Sponsor | Steno Diabetes Center Copenhagen |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Irbesartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors on vascular smooth muscle and adrenal tissue. By blocking angiotensin II signaling, it causes vasodilation and reduces sodium and water retention, thereby decreasing blood pressure and reducing cardiac workload. This mechanism also provides renal protection, particularly beneficial in diabetic patients.
Approved indications
- Hypertension
- Diabetic nephropathy in patients with type 2 diabetes
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Diarrhea
- Musculoskeletal pain
Key clinical trials
- The Randomized Controlled Study of Shenqi Yishen Granules in the Treatment of IgA Nephropathy (NA)
- A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia (PHASE3)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Impact of a Treatment With Angiotensin Receptor Blocker on Outcome After Acute Kidney Injury in Patients Discharged From the ICU. (PHASE3)
- ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC) (PHASE2)
- Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients (PHASE4)
- A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PHASE3)
- Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Irbesartan treatment CI brief — competitive landscape report
- Irbesartan treatment updates RSS · CI watch RSS
- Steno Diabetes Center Copenhagen portfolio CI